Literature DB >> 27220666

The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK.

J Rudolph1, A Heine1, T Quast2, W Kolanus2, J Trebicka3, P Brossart1, D Wolf1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27220666     DOI： 10.1038/leu.2016.155

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs.

Authors:  R Förster; A Schubel; D Breitfeld; E Kremmer; I Renner-Müller; E Wolf; M Lipp
Journal:  Cell       Date:  1999-10-01       Impact factor: 41.582

Review 2.  Dendritic-cell trafficking to lymph nodes through lymphatic vessels.

Authors:  Gwendalyn J Randolph; Veronique Angeli; Melody A Swartz
Journal:  Nat Rev Immunol       Date:  2005-08       Impact factor: 53.106

3.  Rapid leukocyte migration by integrin-independent flowing and squeezing.

Authors:  Tim Lämmermann; Bernhard L Bader; Susan J Monkley; Tim Worbs; Roland Wedlich-Söldner; Karin Hirsch; Markus Keller; Reinhold Förster; David R Critchley; Reinhard Fässler; Michael Sixt
Journal:  Nature       Date:  2008-05-01       Impact factor: 49.962

4.  Differential requirement for ROCK in dendritic cell migration within lymphatic capillaries in steady-state and inflammation.

Authors:  Maximilian Nitschké; David Aebischer; Michael Abadier; Simone Haener; Matije Lucic; Benjamin Vigl; Hervé Luche; Hans Jörg Fehling; Oliver Biehlmaier; Ruth Lyck; Cornelia Halin
Journal:  Blood       Date:  2012-07-31       Impact factor: 22.113

5.  JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms.

Authors:  Sowmya Parampalli Yajnanarayana; Thomas Stübig; Isabelle Cornez; Haefaa Alchalby; Kathrin Schönberg; Janna Rudolph; Ioanna Triviai; Christine Wolschke; Annkristin Heine; Peter Brossart; Nicolaus Kröger; Dominik Wolf
Journal:  Br J Haematol       Date:  2015-03-30       Impact factor: 6.998

6.  JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.

Authors:  Kathrin Schönberg; Janna Rudolph; Maria Vonnahme; Sowmya Parampalli Yajnanarayana; Isabelle Cornez; Maryam Hejazi; Angela R Manser; Markus Uhrberg; Walter Verbeek; Steffen Koschmieder; Tim H Brümmendorf; Peter Brossart; Annkristin Heine; Dominik Wolf
Journal:  Cancer Res       Date:  2015-04-01       Impact factor: 12.701

7.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Solveig Nora Daecke; Stephanie Wallner; Sowmya Parampalli Yajnanarayana; Christian Kurts; Dominik Wolf; Peter Brossart
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

8.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

9.  Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation.

Authors:  F Sallusto; P Schaerli; P Loetscher; C Schaniel; D Lenig; C R Mackay; S Qin; A Lanzavecchia
Journal:  Eur J Immunol       Date:  1998-09       Impact factor: 5.532

10.  Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348).

Authors:  T Zhou; S Georgeon; R Moser; D J Moore; A Caflisch; O Hantschel
Journal:  Leukemia       Date:  2013-07-04       Impact factor: 11.528
View more
  14 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

2.  Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review.

Authors:  Yizhou Peng; Li Meng; Xuemei Hu; Zhiqiang Han; Zhenya Hong
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003

3.  Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.

Authors:  Palma Manduzio
Journal:  Ther Clin Risk Manag       Date:  2017-02-13       Impact factor: 2.423

Review 4.  Tumor-related interleukins: old validated targets for new anti-cancer drug development.

Authors:  Sarra Setrerrahmane; Hanmei Xu
Journal:  Mol Cancer       Date:  2017-09-19       Impact factor: 27.401

Review 5.  Immunotherapy in Myeloproliferative Diseases.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

6.  Defective migration and dysmorphology of neutrophil granulocytes in atypical chronic myeloid leukemia treated with ruxolitinib.

Authors:  Lea Bornemann; Marc Schuster; Saskia Schmitz; Charlyn Sobczak; Clara Bessen; Simon F Merz; Karl-Heinz Jöckel; Thomas Haverkamp; Matthias Gunzer; Joachim R Göthert
Journal:  BMC Cancer       Date:  2020-07-13       Impact factor: 4.430

Review 7.  Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?

Authors:  Klara Klein; Dagmar Stoiber; Veronika Sexl; Agnieszka Witalisz-Siepracka
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

8.  Targeting senescent cells: approaches, opportunities, challenges.

Authors:  Cayetano von Kobbe
Journal:  Aging (Albany NY)       Date:  2019-11-30       Impact factor: 5.682

Review 9.  Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib.

Authors:  Elena Maria Elli; Claudia Baratè; Francesco Mendicino; Francesca Palandri; Giuseppe Alberto Palumbo
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

10.  The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.

Authors:  Martina Barone; Lucia Catani; Francesca Ricci; Marco Romano; Dorian Forte; Giuseppe Auteri; Daniela Bartoletti; Emanuela Ottaviani; Pier Luigi Tazzari; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Oncoimmunology       Date:  2020-06-23       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.